DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Achyut Healthcare Ltd (ACHYUT) share price today?

Achyut Healthcare Ltd (ACHYUT) is trading at ₹7.36 on the BSE, up 3.66% on the day. Source: DocStoX.

What is the PE ratio of Achyut Healthcare Ltd?

Achyut Healthcare Ltd has a price-to-earnings (PE) ratio of 368.0 in the Healthcare sector.

What is the market capitalisation of Achyut Healthcare Ltd?

Achyut Healthcare Ltd has a market capitalisation of approximately ₹180 crore.

Achyut Healthcare Ltd

ACHYUT·BSE·Healthcare

₹7.36▲ +0.26 (+3.66%)

Healthcare · Pharmaceuticals & Biotechnology

A steady, established business

Day₹6.80

₹7.45

52W₹4

₹1056%

Open

₹7.10

High

₹7.45

Low

₹6.80

Prev Close

₹7.10

Volume

1.58L

VWAP

₹7.24

Snapshot

Key fundamentals

Market Cap

₹180 Cr

P/E Ratio

368.00Expensive

P/B Ratio

4.89

EPS

₹0.02

Book Value

₹1.45

ROE

1.75%Weak

ROCE

2.26%Weak

Dividend Yield

0.00%

Debt / Equity

0.01Low

Face Value

₹1.00

52W High

₹10.04

52W Low

₹3.90

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Avoid

None moatHigh uncertainty

Fair value estimate

₹1

▼ 80.5%downside

Trading at ₹7 — 81% above our estimate

BearFair valueBull

₹1₹1₹3

/100

Business quality — Watch the fundamentals

Growth 50Profitability 45Efficiency 0Valuation 50

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet
Weak returns on equity (2%)

Strengths

Virtually debt-free balance sheet

Risks

Weak returns on equity (2%)
Expensive — trades at 368× earnings

How we got there

Fair value methods

Residual income

2% ROE fading to 12% over ~3 yrs, on ₹1 book

₹1

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹3

Analyst target

No analyst coverage

—

Blended fair value₹1

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet

Bear case

Weak returns on equity (2%)
Expensive — trades at 368× earnings

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

368.0Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

1.8%Weak

Above 15% is considered healthy for Indian equities

ROCE

2.3%Weak

Above 18% means capital is working hard

Debt/Eq

0.01Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹180 Cr

P/B

4.89

EPS

₹0.02

Div Yield

—

What changed

Recent changes

Foreign investors-0.1% stake last quarter
Promoters-0.31% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 368.0×

Growth

Strong

+63% rev CAGR

Profitability

Modest

1.8% ROE

Financial health

Rock solid

D/E 0.01

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹11.41L Cr

Trades304

VWAP₹7.24

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+62.5%

+112.1%

10Y

—

Profit

+6.8%

+94.7%

10Y

—

EPS

+224.0%

+76.2%

10Y

—

Profile

Pros

Company is almost debt free.
Debtor days have improved from 76.8 to 45.7 days.
Company's working capital requirements have reduced from 834 days to 91.0 days

Watch-outs

Cons

Stock is trading at 4.89 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
Company has a low return on equity of 1.58% over last 3 years.
Promoter holding has decreased over last 3 years: -6.45%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Promoters trimmed their stake by 0.31 pts; foreign investors sold 0.13 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

47%

Promoter

Promoters

47.4%-0.31

Public

42.8%-0.24

FII / FPI

5.1%-0.13

DII

0.0%0.00

Others

4.6%

Total shareholders

518-1 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter47.40%

FII5.13%

Public42.83%

Others4.64%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1996, Achyut Healthcare Ltd is a pharmaceutical trading company dealing in API, Pharmaceutical products, medical devices, etc.[1]